Welcome to our dedicated page for SciSparc Ltd. SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd. reports that in August 2025 certain investors converted portions of previously issued convertible debentures into equity. The debentures were originally issued in an aggregate principal amount of $4.2 million and are convertible into ordinary shares. Based on conversion notices submitted by investors, the company issued 999,528 ordinary shares upon conversion of outstanding principal and accrued interest. After these issuances, SciSparc had 1,622,273 ordinary shares issued and outstanding as of August 28, 2025, and $175,000 principal amount of debentures remained outstanding.
SciSparc Ltd. reports that its shareholders have approved a merger with a leading parallel vehicle importer in Israel. The company also notes that shareholders of AutoMax, the target business, have approved merging AutoMax with SciSparc.
The report furnishes two press releases as exhibits describing these approvals and incorporates this information into multiple existing SciSparc registration statements on Forms F-3 and S-8, meaning the merger details become part of those offering documents going forward.
SciSparc Ltd. reports that its shareholders approved all proposals presented at an adjourned special general meeting held on August 26, 2025. The proposals were approved by the required majority under Israeli Companies Law and the company’s amended and restated articles of association, as described in the proxy statement/prospectus sent to shareholders.
The company also states that this report is incorporated by reference into several of its existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this update as part of their disclosed information.
SciSparc Ltd. convened a Special General Meeting of Shareholders on August 25, 2025, but the meeting was adjourned due to lack of quorum. The adjourned Special Meeting is scheduled for August 26, 2025 at 8:00 a.m. Eastern / 3:00 p.m. Israel time at the company’s Tel Aviv offices.
If a quorum is still not present within half an hour of the new start time, any shareholders present in person or by proxy, or who have delivered a proxy card, will constitute a quorum and may vote on the meeting matters. Proxy cards already delivered will be used at the adjourned meeting.
SciSparc Ltd. furnished a Form 6-K to update investors about a new development in its collaboration with Clearmind. The company reported that on August 7, 2025 it issued a press release titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.” This indicates the partners are pursuing patent protection for a combination therapy aimed at metabolic conditions such as obesity and elevated blood sugar levels.
The Form 6-K also states that this update is incorporated by reference into SciSparc’s existing shelf registration statements on Form F-3 and its equity compensation registration statements on Form S-8, meaning the disclosure becomes part of those securities offering documents.
SciSparc announced that shareholders approved all proposals at their adjourned annual general meeting held on June 26, 2025. The meeting resulted in the approval of two significant documents:
- A new amended and restated articles of association
- An updated compensation policy for executive officers and directors
These approvals were obtained with the requisite majority in accordance with Israeli Companies Law and the company's existing articles of association. The proposals were previously detailed in a proxy statement furnished to the SEC on May 21, 2025.
The Form 6-K filing will be incorporated into multiple company registration statements, including several Form F-3s (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408) and Form S-8s (File Nos. 333-278437, 333-225773, 333-286791). The document was signed by Oz Adler, Chief Executive Officer.